(Q34924266)

5 August 2017

1 reference

title

Cytokines in multiple sclerosis: methodological aspects and pathogenic implications (English)

1 reference

5 August 2017

0 references

2

M Kouwenhoven

1 reference

5 August 2017

V Ozenci

1

1 reference

5 August 2017

H Link

series ordinal

3

1 reference

5 August 2017

language of work or name

1 reference

1 October 2002

1 reference

Multiple Sclerosis Journal

5 August 2017

published in

1 reference

5 August 2017

volume

8

1 reference

5 August 2017

issue

5

1 reference

5 August 2017

page(s)

396-404

1 reference

HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Exacerbations of multiple sclerosis in patients treated with gamma interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Anti-inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Review: cytokines and the pathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Virus-reactive and autoreactive T cells are accumulated in cerebrospinal fluid in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

The role of CD40 ligand in costimulation and T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Selective expression of an interleukin-12 receptor component by human T helper 1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Interleukin-12 and perforin mRNA expression is augmented in blood mononuclear cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Increased release of interleukin-12p40 in MS: association with intracerebral inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Proinflammatory cytokines regulate antigen-independent T-cell activation by two separate calcium-signaling pathways in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Multiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Augmented expression of tumour necrosis factor-alpha and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Interleukin 6 and its receptor: ten years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

IL-6 and APPs: anti-inflammatory and immunosuppressive mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Interleukin-6 is elevated in plasma in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

The effect of interferon beta-1b on lymphocyte-endothelial cell adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Mechanisms of inflammation in MS tissue: adhesion molecules and chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Immune regulation within the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

IL-6 detection in multiple sclerosis brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Genetic models for CNS inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Mechanisms of immune injury in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Identification of autoantibodies associated with myelin damage in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Significant correlation between IL-10 levels and IgG indices in the cerebrospinal fluid of patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS837RR

10.1191/1352458502MS837RR

21 January 2018

Identifiers

DOI

1 reference

release_b3rj5ydkz5b57gtvgxstrsqyyq

5 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b3rj5ydkz5b57gtvgxstrsqyyq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference